Abstract
Lanadelumab, a kallikrein inhibitor, was approved for prophylactic treatment of hereditary angioedema (HAE) in 2018. The HAE-subtype characterized by normal C1 esterase inhibitor levels (NC1-INH-HAE) is highly burdensome and complex to treat. This chart review reports the real-world effectiveness of lanadelumab in patients with NC1-INH-HAE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
